In the phase III trial ClarIDHy (NCT02989857), 185 patients (91% IHCC) with IDH1-mutated cholangiocarcinoma who had received 1 or 2 lines of prior therapy were treated with either ivosidenib or placebo. This evidence concerns the gene IDH1 and cholangiocarcinoma.